1. Pink Sheet
  2. >>Market Access

Patent Cliff Likely Accelerated By Two Years For Most Drugs On Medicare Price Negotiation List

 
• By Cathy Kelly and Nancy Pham

The Class of ’26 of Medicare Price Negotiation University is now on stage. Our infographic profiles who they are and where they come from, breaking down the $50.5B in gross annual Part D spending, about 20% of the total.

Patent Cliff
• Source: Nielsen Hobbs; the Pink Sheet | Shutterstock images

This story is part of the Pink Sheet’s coverage of the selection of the first 10 drugs for Medicare price negotiation.

Bristol Myers Squibb/Pfizer

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Medicare

More from Government Payers